Biohaven Ltd. (NYSE:BHVN - Free Report) - Investment analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Biohaven in a research note issued to investors on Tuesday, January 21st. Cantor Fitzgerald analyst C. Duncan expects that the company will post earnings per share of ($6.05) for the year. Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Biohaven's current full-year earnings is ($8.85) per share.
Several other research analysts have also commented on BHVN. Bank of America increased their price target on shares of Biohaven from $52.00 to $62.00 and gave the stock a "buy" rating in a research note on Tuesday, September 24th. TD Cowen increased their target price on shares of Biohaven from $55.00 to $75.00 and gave the stock a "buy" rating in a research report on Wednesday, November 13th. Sanford C. Bernstein upped their price target on Biohaven from $55.00 to $66.00 and gave the stock an "outperform" rating in a research note on Tuesday, September 24th. HC Wainwright reissued a "buy" rating and issued a $59.00 price objective on shares of Biohaven in a research note on Tuesday, December 17th. Finally, Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 target price (up previously from $58.00) on shares of Biohaven in a research report on Wednesday, December 4th. Thirteen research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Biohaven presently has an average rating of "Buy" and an average price target of $63.00.
Check Out Our Latest Stock Analysis on Biohaven
Shares of NYSE:BHVN opened at $39.09 on Wednesday. Biohaven has a 12-month low of $26.80 and a 12-month high of $62.21. The firm has a fifty day moving average of $40.80 and a two-hundred day moving average of $42.43. The firm has a market capitalization of $3.95 billion, a P/E ratio of -4.18 and a beta of 1.29.
Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($1.70) earnings per share for the quarter, missing analysts' consensus estimates of ($1.67) by ($0.03).
A number of institutional investors have recently modified their holdings of BHVN. Stifel Financial Corp grew its position in Biohaven by 0.4% in the third quarter. Stifel Financial Corp now owns 6,509,261 shares of the company's stock valued at $325,268,000 after purchasing an additional 28,684 shares in the last quarter. Janus Henderson Group PLC raised its stake in Biohaven by 5.6% in the 3rd quarter. Janus Henderson Group PLC now owns 6,226,393 shares of the company's stock valued at $311,142,000 after acquiring an additional 328,099 shares during the period. Farallon Capital Management LLC lifted its holdings in Biohaven by 181.4% during the 2nd quarter. Farallon Capital Management LLC now owns 2,248,000 shares of the company's stock valued at $78,028,000 after purchasing an additional 1,449,000 shares during the last quarter. Geode Capital Management LLC boosted its position in Biohaven by 2.6% during the third quarter. Geode Capital Management LLC now owns 1,714,612 shares of the company's stock worth $85,696,000 after purchasing an additional 44,174 shares during the period. Finally, Point72 Asset Management L.P. boosted its position in Biohaven by 745.9% during the third quarter. Point72 Asset Management L.P. now owns 1,500,284 shares of the company's stock worth $74,969,000 after purchasing an additional 1,322,922 shares during the period. 88.78% of the stock is currently owned by institutional investors.
In other Biohaven news, Director John W. Childs acquired 29,000 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average cost of $35.94 per share, for a total transaction of $1,042,260.00. Following the transaction, the director now owns 2,368,741 shares of the company's stock, valued at $85,132,551.54. This trade represents a 1.24 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 16.00% of the stock is owned by insiders.
Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Biohaven, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biohaven wasn't on the list.
While Biohaven currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.